2026 Agenda: Day 3 - Wednesday 14 January - PT (Pacific Time, GMT-08:00)
Not all commercial routes to Europe are equal. This fireside chat will explore options beyond outsourcing or going it alone and will highlight the real operational blockers that slow European market entry. You will take away practical lessons from leaders who have turned European complexity into commercial momentum.
- Grant Castor - Senior Vice President, Commercial Strategy & Operations, Sentynl
- Alastair MacDonald - Head, Medical Affairs & Growth Strategy, Sciensus
After a challenging few years, the biotech sector may be entering a period of renewed opportunity. This session will explore emerging investment trends, acquisitions, and the factors driving optimism for the next wave of biotech innovation.
- Kimberly Ha - Founder & CEO, KKH Advisors
- James Healy - Managing Partner, Sofinnova Investments
- Andrew Lam - Managing Director, Head, Biotech Private Equity, Ally Bridge Group
- Michael Meyers - Vice Chairman, Head of M&A and Strategic Advisory Services, H.C. Wainwright & Co., LLC
- Wonhee Oh - VP, Healthcare Investment Banking, J.P. Morgan
- Asish Xavier - VP, Venture Investments, Johnson & Johnson Innovation
AI and quantum computing are reshaping the pharmaceutical industry by optimizing every stage of the drug development lifecycle. Hear from our panel of experts how these technologies allow researchers to uncover insights from large datasets and identify complex patterns. Beyond drug discovery, AI is poised to transform therapeutic development across research, clinical trials, regulatory submissions, and manufacturing processes.
- Beth Rogozinski - CEO, Oncoustics
- Noura Daadaa - BioTech Vertical Lead - Strategic Startups, Google
- Priyanka Rao - Venture Fellow, H/L Ventures
- Rachel Ravens - Co-Founder & Managing Partner, 46Health
- MaryAnne Rizk - Managing Director, Head of Healthcare & Life science Clinical Strategy, Amazon Web Services (AWS)
Women’s health goes far beyond maternal and reproductive care, representing a substantial opportunity for value creation and societal impact. The Gates Foundation said it would commit $2.5 billion through 2030 to support dozens of different approaches for improving women’s health, from new medicines to prevent maternal mortality to vaccines to curb infections that disproportionately affect women. Is women’s health finally getting the attention it deserves? This session will explore emerging innovations and investment opportunities driving the next wave of transformation in women’s healthcare.
- Lori Ellis - Market Intelligence Advisor, Consultant
- Jessica Federer - Board Member, Angelini Ventures
- Kristina Simmons - Managing Partner, Overwater Ventures
- Tracy Warren - Senior Managing Director, Go Red for Women Fund, AHA Ventures, American Heart Association
- Alice Zheng - Partner, Foreground Capital
The traditional closing discussion at Biotech Showcase where journalists are invited to discuss what was “heard around the square” and Biotech Showcase during the most important week in the biotech calendar.
- Virginia Amann - Founder, ENTENTE Network
- Annalee Armstrong - Senior Editor, BioSpace
- Allison DeAngelis - Reporter, Biotech Startups and Venture Capital, STAT
- Kyle LaHucik - Senior Reporter, Endpoints News
- Ron Leuty - Senior Reporter, San Francisco Business Times
- Alex Philippidis - Senior Business Editor, GEN
Explore the latest breakthroughs in neuroscience, from novel therapeutic approaches to cutting-edge diagnostics. Join this panel to learn about their strategies, technologies, and collaborations, shaping the next generation of brain health solutions.
- Walter Greenleaf - Neuroscientist & Product Developer, Stanford University
- Ryan Field - CEO, Kernal
- Ana Maiques - CEO & CoFounder, Neuroelectrics
- Jack O’Meara - CEO, Aerska
- Maha Radhakrishnan - Executive Partner, Sofinnova Investments
Hear from this panel how cutting-edge approaches are reshaping treatment paradigms and unlocking new opportunities in immune-based therapeutics.
- David Ewing Duncan - Journalist, Author, Researcher
- Hans Keirstead - Chairman, Immunis, Inc.
- Yi Larson - CEO & Founder, Expedition Therapeutics
- Wyatt McDonnell - CEO, Infinimmune
- Niels Riedemann - CEO, InflaRx
In 2026, can early-stage biotech companies expect a rise in venture capital activity? Leading investors will explore strategies to leverage increased investment, secondary markets and IPO opportunities, strategic partnerships, and investment trends shaping biotech ventures.
- Christina Jenkins - Co-Founder & General Partner, Convergent Ventures
- Themasap Khan - Co-founder & Partner, Luma Group
- Michael Langer - Co-Founder & Managing Partner, T.Rx Capital
- Jarod Rutledge - Head of Biotech Investment, Starbloom Capital